Biograph.

What Biograph actually is

A membership clinic, quietly founded in 2016 and opened publicly in early 2025, running the preventive diagnostic spread that constitutes the actual minimum-credible workup for the patient who wants their next forty years to look like the previous forty. It identifies many quality-of-life risks — cardiovascular, metabolic, brain, cancer — before symptoms force the conversation.

The brand emerged from stealth in 2025 with the opening of its New York clinic and plans to expand beyond. The flagship Biograph San Francisco Bay Area clinic opened to a small cohort of patients in 2020, and the membership has since grown into the thousands.

The model is annual: a single intake day of up to six hours, structured follow-up across the year, and a re-baseline twelve months later. The depth of the workup is comparable to YEARS at the upper tier; the model differs in being explicitly longitudinal rather than punctual.

What you actually get

The Core membership ($7,500 in the first year; renewal pricing depends on the recommended tier) buys 20+ assessments. Whole-body MRI. DEXA composition. CPET-grade VO₂ max with lactate threshold. Genetic testing. The hormonal and metabolic depth is significant; the cardiovascular workup includes a coronary calcium score by default.

Black membership ($17,500 in the first year) extends to 30+ assessments. The major additions are CT coronary angiography (a step beyond calcium scoring), multi-cancer early detection (Galleri-class liquid biopsy), multi-modal brain health imaging including specialist neurocognitive review, a low-dose lung CT, at-home sleep testing and a mid-year lab panel. The price step is real; the diagnostic step is also real.

Both tiers include the work that most clinics fail at: structured clinical touchpoints across the year (six at Core, thirteen at Black), the protocol revision, the specialist referrals when the data warrants them.

On the conflict-of-interest question

Biograph is one of the few American clinics in the upper tier we believe deserves credit on this axis. The membership is the revenue line. There is no peptide protocol upsell and no NAD+ infusion suite. In-house treatment exists in one bounded form: since August 2026 the Women’s Health Program offers menopausal hormone therapy under clinician oversight where clinically appropriate, which is guideline-backed care rather than an optimisation upsell. Specialists, when needed, are referred outside the membership.

This is not pure independence — the clinic will still want you to renew next year — but the financial geometry is meaningfully different from a clinic that profits from each protocol it adds.

Where it falls short

Two structural caveats.

Multi-cancer early detection and full-body MRI both carry a meaningful false-positive cost. Biograph’s clinical team handles the resulting workups well, in our reading, but the reader should know that ‘urgent finding’ counts the way they do — in published data on Galleri-class assays, the positive predictive value sits around 38–43%, meaning a meaningful share of positives turn out to be benign on workup. The downstream MRI-driven cost and anxiety are real.

The membership is currently US-only. International readers, particularly in Europe, have closer-to-home options at YEARS or Hirslanden.

The verdict

The closest American answer to YEARS in this directory. Same diagnostic-first instinct, longer-running membership structure, an explicit five-pillar prevention thesis to organise the work around. For the US-based reader prepared to commit to an annual cadence, Biograph is — currently — the highest-scoring choice we have.

A clinic that bills annually for the longitudinal work is closer to the right model than a clinic that bills protocol-by-protocol for the year of work that follows.

Questions readers ask about Biograph

— 01

How much does Biograph cost?

Pricing for Biograph, as checked in September 2026: Core membership at $7,500 per year; Black membership at $17,500 per year.

— 02

Does Biograph earn from the treatments it recommends?

Only to a limited degree, in our assessment. Diagnostic-first membership; in-house treatment is limited to evidence-based care such as menopausal hormone therapy in the Women's Health Program (launched August 2026). Specialist referrals are made out-of-network. The membership itself is the revenue line, not protocol upsells. Biograph scores 22/25 on conflict freedom.

— 03

Is Biograph physician-led?

Yes. Medical leadership: Dr. Michael Doney (Executive Medical Director). Biograph scores 23/25 on medical supervision.

— 04

How does Biograph rank among longevity clinics?

Biograph ranks #2 of 19 in the 2026 Longevity Clinics ranking, with 92/100 (Excellent). The closest American answer to YEARS. Same diagnose-first instinct, longer-running membership cadence.